CANNOT BUY ONLINE

Bought more this morning...it's looking good!

good for you, still have plenty myself.

How do you think the sp is going to play out?...I've seen on other boards people saying that there's too many shares in circualtion for the sp to strengthen significantly,if at all...

just waiting for more contract news, which they're picking up all the time. They could consolidate if things get good.

Looks like something stirring here, news immenent I reckon, been creeping up last couple of days.....hopefully another contract win.,.

'bout time too !...nice rise today as well!

This is coming good at last...good story unfolding here..I hope! (imho)

its in the news - BUYYYYYYYYYYYYYYYYYYYYYYYYYY! imo

spread the word...

http://www.bbc.co.uk/news/health-11763681

16 November 2010 Last updated at 09:55 GMT Share this pageFacebookTwitter ShareEmail Print Stem cells used in stroke trialBy Pallab Ghosh

Science correspondent, BBC News Trial patients will get progressively higher doses of stem cells Continue reading the main story
Related stories
Q&A: Stem cells
Stem cells repair stroke damage
Doctors in Glasgow have injected stem cells into the brain of a stroke patient in an effort to find a new treatment for the condition.

The elderly man is the first person in the world to receive this treatment - the start of a regulated trial at Southern General Hospital.

He was given very low doses over the weekend and has since been discharged - and his doctors say he is doing well.

Critics object as brain cells from foetuses were used to create the cells.

The patient received a very low dose of stem cells in an initial trial to assess the safety of the procedure.

Over the next year, up to 12 more patients will be given progressively higher doses - again primarily to assess safety - but doctors will be looking closely to see if the stem cells have begun to repair their brains and if their condition has improved.

Early stages

Continue reading the main story

Start Quote
We hope that in the future it will lead to larger studies
End Quote
Professor Keith Muir

Glasgow University
The company making the stem cells says the trial has ethical approval from the medicine's regulator.

It also points out that foetuses were used in the very early stages of the research and are now no longer used.

Professor Keith Muir, a neuroscientist at Glasgow University and a consultant neurologist at Southern General Hospital, said if the trials went well it would lead to more detailed research.

"We hope that in the future it will lead to larger studies to determine the effectiveness of stem cells on the disabilities that result from strokes," he said.

The first group of patients to receive the treatment will be men over 60 who have shown little or no improvement in their condition over a number of years.

It is an ideal group to assess the safety of the procedure - doctors will be keen to know first of all that the treatment makes them no worse.

But having such a precisely defined group will enable doctors and scientists to compare like with like if they notice any improvement - even in these early stages.

If these trials show promise, doctors plan larger trials on a more varied group of patients. The earliest this could begin is in two years' time.

There will be more focus on assessing the effectiveness, if any, of the stem cell treatment and on which groups it works best.

Patients will be monitored for two years, followed by longer term procedures after that.

Advertisement
Professor Anthony Rudd of St Thomas' Hospital explains what happens during and after a stroke

The announcement from the Glasgow team comes a few weeks after the US firm Geron said it had begun its clinical trials on a patient to develop a treatment for paralysis.

The development of stem cell treatments is still at a research stage and it is likely to be many years before becoming widely available.

But new potential treatments are now beginning to make their way from the scientist's laboratory into the doctor's clinic.

Strokes kill around 67,000 people in the UK every year, according to the Stroke Association.

The charity says it is the third most common cause of death in England and Wales after heart disease and cancer.

The disabilities suffered by patients also have a greater impact than any other chronic disease, it adds.

already in and waiting......fantastic news but maybe 2 years for results, lots of other things going on i'm sure to keep sp climbing.,.

It's moving up nicely ! Glad I stuck with this one...will continue to hold!

satisfactory day at the office - lol
hope you guys caught it in time if not already
kerrrrrrchinnnnnnnnnngggg!

reckon there will be somemore to come tomorrow morning.,.

me too - rns today out more good news!

kerrrchinnnnng +!

.82 is broker target before yesterday's news!! lol

Am out for now at 62, halifax buggered about when i wanted to sell at 68.....but 2.5 times my input is lovely. back in when the dust settles.,. ;))

gibby did you sell or hold??

Bought some more y'day at 33.....

From traderstreasure.com

Angel on your shoulder!
19/11/10 08:20 Filed in: Angel Biotechnology Hldgs
This rather small company cant quite produce fast enough for the customers out there! They are soon to re-open a mothballed facility which can only have a positive effect on the SP.
More of a long term hold on this one, although you will see some big jumps along the way!

So did I also at 33 mostly because Halifax had a free deal time midday so good value and extra shares with the 11.95.,. last time held at 24 sold at 61, nice profit now sit and wait for next spike. happy days.

feel another quick profit coming:

ANGEL BIOTECHNOLOGY HOLDINGS PLC

("Angel" or "the Company")



Angel and Materia Medica announce new GMP Manufacturing Contract



Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce the signing of a new GMP Manufacturing contract with Materia Medica Holdings, a leading pharmaceutical company in Russia. The contract for process development and GMP manufacture of specific antibodies is valued at circa 1.53 million. The GMP manufacture will complete in late 2012.

Commenting on the contract, Gordon Sherriff, Angel's Chief Operating Officer said: "We have been working with Materia Medica for over 3 years now and this is the 6th contract for the process development and GMP manufacturing of their innovative products. We are very pleased to have again found the technical solutions which Materia Medica requires for this latest project, and to be able to continue our commitment to working with Materia Medica by supporting the regulatory compliant manufacture of its pipeline of products. Supporting clients with advanced biologics through often complex regulatory hurdles is a significant part of Angel's service offering.

Sergey Tarasov, of Materia Medica Holding R&D department, said: "We are delighted to award a further GMP contract to Angel. This product is key to our product portfolio and Angel's continued ability to identify a regulatory compliant manufacturing route demonstrates the strong relationship our companies have built over the past 3 years. Angel provides a fully integrated service offering, with the necessary manufacturing and regulatory experience to allow licensing of our products in the EU. As Materia Medica's established manufacturer for our antibody based products we look forward to working with Angel on future projects.

SP pulling back abit today but there should be more spikes coming along..there's lots of news coming along during 2011....so will stay in for time being!